Introducing T-Guard™

T-Guard™ is a medicine currently under development that safely and swiftly ‘resets’ the body’s immune system. It shows potential in the effective treatment of certain life-threatening immune conditions, such as transplant-related rejection, Graft versus Host Disease (GVHD), acute solid-organ rejection and several severe autoimmune diseases.

Targeted Action

After injection into the body, T-Guard destroys mature T- and NK cells, with a strong preference for activated T cells (the trouble makers). T-Guard can do this, because it consists of two anti-T-cell antibodies that act against specific cell membrane-antigens, CD3 and CD7. Each antibody in T-Guard is conjugated to an immunotoxin that prevents the cells from making new proteins, thereby inducing pogrammed cell death (apoptosis).

Read more about Immunotoxins

Unique properties

The particular combination of immunotoxins used to construct T-Guard provides a unique blend of synergistic efficacy, narrow specificity and multiple gentle mechanisms of action. Its action is unparalleled by any immunosuppressive product currently available commercially.

Read more about the Unique properties

Impressive Results

When administered in a clinical pilot-study as a one-week course of therapy, T-Guard induced the swift and efficient removal of circulating T cells, followed by impressive biological and clinical responses without causing severe toxicities. Subsequent new T cell development was not accompanied by a recurrence of GVDH. Indicating that T-Guard is capable of ‘resetting’ the immune system.


T-Guard was discovered and developed in the Hematology Department of the Radboud University Nijmegen Medical Center in Nijmegen – One of the Netherlands’ most well-known academic hospitals. It has already proved effective in a clinical pilot study for the treatment of severe acute GVHD.


Xenikos is developing T-Guard for approval as an orphan drug for treating acute Graft versus Host Disease (GVHD) and potentially other indications, in which, hyper-reactive-, misdirected- or malignant T cells are implicated, such as solid organ rejection, autoimmune diseases and T cell derived blood cancers.

See also Alternative Indications